SCHEMBL30765639

SCHEMBL30765639

CCCCOC(=O)n1c(CN)cc2cnccc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.41
KMT2A Q03164 10/20 0.39
ALDH1A1 P00352 2/20 0.39
TSHR P16473 4/20 0.39
RAB9A P51151 2/20 0.39
MAPT P10636 5/20 0.38
MEN1 O00255 5/20 0.38
POLB P06746 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
LMNA P02545 4/20 0.38
BCHE P06276 1/20 0.35
HPGD P15428 2/20 0.35
NTRK1 P04629 1/20 0.34
TP53 P04637 1/20 0.34
HTT P42858 1/20 0.34
ROCK2 O75116 2/20 0.34
CYP1A2 P05177 2/20 0.34
CYP2C9 P11712 2/20 0.34
CYP2C19 P33261 2/20 0.34
CYP3A4 P08684 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27108521 0.80 NR1H2 (0.46) CYP2C9
Hydrochloric Acid SCHEMBL27147491 0.79 NR1H2 (0.46) CYP2C9
SCHEMBL31558535 0.77 HDAC8 (0.38) L3MBTL1KMT2AALDH1A1MAPTMEN1
SCHEMBL17347544 0.76 NR1H2 (0.38) L3MBTL1NTRK1CYP2C9
SCHEMBL30659324 0.74 L3MBTL1 (0.46) L3MBTL1KMT2AALDH1A1TSHRRAB9A
SCHEMBL18848182 0.71 NR1H2 (0.40) CYP2C9
SCHEMBL23099838 0.70 LMNA (0.44) L3MBTL1KMT2AALDH1A1TSHRRAB9A
Hydrochloric Acid SCHEMBL27153869 0.69 NR1H2 (0.46) CYP2C9
SCHEMBL17644215 0.68 KMT2A (0.46) L3MBTL1KMT2AALDH1A1TSHRRAB9A
SCHEMBL23461159 0.68 CYP2A6 (0.40) ALDH1A1RAB9AMAPTPOLBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed